Echo Therapeutics to Present at the Noble Financial Capital Markets' Ninth Annual Equity Conference

  Echo Therapeutics to Present at the Noble Financial Capital Markets' Ninth
                           Annual Equity Conference

PR Newswire

PHILADELPHIA, Jan. 15, 2013

PHILADELPHIA, Jan. 15, 2013 /PRNewswire/ --Echo Therapeutics, Inc. (NASDAQ:
ECTE), a company developing its needle-free Symphony^® tCGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring system,
today announced that Patrick T. Mooney, M.D., Chairman and CEO of Echo
Therapeutics will present at "NINE", Noble Financial Capital Markets' Ninth
Annual Equity Conference.


Dr. Mooney will make a corporate presentation to prospective corporate
partners and investors at 10:00 AM EST on Tuesday, January 22^nd. The
Company's presentation will be delivered at the Hard Rock Hotel in Hollywood,

At the time of the presentation, a live audio and high-definition video
webcast of Dr. Mooney's presentation and a copy of the presentation materials
will be available in the Events section of the company's website at, or through the Noble Financial websites: or Echo recommends registering at least 10
minutes prior to the start of the presentation to ensure timely access. You
will require a Microsoft SilverLight viewer (a free download from the
presentation link) to participate. The webcast and presentation will also be
archived on for 90 days following the event.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive,
wireless, transdermal continuous glucose monitoring system. Our target is
patients who could benefit from glucose monitoring in the hospital setting,
including critical care. Significant opportunity also exists for patients
with diabetes to use Symphony in the outpatient setting. Echo is also
developing its needle-free skin preparation component of Symphony, the
Prelude^® SkinPrep System, as a platform technology to enhance drug delivery
of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Echo's ongoing
studies, including the safety and efficacy of Echo's Symphony tCGM System, the
failure of future development and preliminary marketing efforts related to
Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure
additional commercial partnering arrangements, risks and uncertainties
relating to Echo's and its partners' ability to develop, market and sell
diagnostic and transdermal drug delivery products based on its skin permeation
platform technologies, including the Symphony tCGM and Prelude SkinPrep
Systems, the availability of substantial additional equity or debt capital to
support its research, development and product commercialization activities,
and the success of its research, development, regulatory approval, marketing
and distribution plans and strategies, including those plans and strategies
related to its Symphony tCGM and Prelude SkinPrep Systems. These and other
risks and uncertainties are identified and described in more detail in Echo's
filings with the Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the year ended December 31,
2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K.
Echo undertakes no obligation to publicly update or revise any forward-looking

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104

Connect With Us:
- Visit our website at
- Follow us on Twitter at
- Join us on Facebook at

SOURCE Echo Therapeutics, Inc.

Press spacebar to pause and continue. Press esc to stop.